MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
Galectin Therapeutics, Inc. (NASDAQ: GALT)*
Organization & Developments: Galectin
Parents
Galectin Therapeutics, Inc. (NASDAQ: GALT)*
Children
*Based on the Company's understanding of galectin proteins, key mediators of biologic function.
*Galectin Therapeutics is developing carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer
2017: Galectin plunges on NASH cirrhosis midstage miss
2018: Galectin Therapeutics Is On To Something Big - Galectin Therapeutics, Inc. (NASDAQ:GALT)
2018: NASH Pathogenesis: Better Understanding And A Look At Galectin_seekingalpha.com
2019: Galectin In NASH, And The Market Assessment
2019: Galectin Therapeutics: Primed For Takeoff After The Rights Offering And New Clinical Evidence - Galectin Therapeutics, Inc. (NASDAQ:GALT)
2022: Galectin Therapeutics (GALT) Investor Presentation - Slideshow_ seekingalpha.com
2024: Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point
2024: Galectin's MASH treatment reduces varices but fails to hit statistical significance in phase 3 trial
Jumps
*Key People: Galectin
Finance & Acquisitions: Galectin